DJ Bull Pushes Out Timing of Starpharma Profit -- Market...

DJ Bull Pushes Out Timing of Starpharma Profit -- Market Talk

Bell Potter pushes out a profit forecast for Starpharma as management works toget US regulators to support the commercial sale of its VivaGel treatment for bacterialvaginosis. The investment bank now sees Starpharma making a loss in FY19 and FY20 afterrevising a "timeline and quantum of upfront and milestones" from deals for VivaGel BV.Also, Bell Potter now expects Starpharma to get a milestone payment from AstraZeneca inF1H20 while absorbing costs of conducting an additional Phase 3 trial in the US. Still,it remains bullish on the stock with several catalysts looming, including the firstcommercial launch of VivaGel BV in Australia and Europe. ([email protected];@dwinningWSJ) (END) Dow Jones Newswires April 04, 2019 17:51 ET (21:51 GMT)Copyright(c) 2019 Dow Jones & Company, Inc.Friday 05 April 2019 08:51:00.000 AEST